FAQs on Annovis Bio Inc.'s Patent Coverage for Buntanetap's New Crystalline Form

What has Annovis Bio Inc. announced regarding buntanetap?

Annovis Bio Inc. announced the successful transfer and expansion of its intellectual property to fully cover both the original and new crystalline forms of buntanetap, with patents protected through 2046.

Why is the new crystalline form of buntanetap significant?

The new crystalline form offers improved stability with bioequivalence confirmed in animal and human studies, making it a significant advancement in the treatment of neurodegenerative diseases.

How does the patent coverage benefit Annovis Bio Inc.?

The comprehensive patent portfolio, including composition of matter, mechanism of action, and use in multiple indications, secures Annovis Bio Inc.’s intellectual property and competitive edge through 2046.

Where was the new form of buntanetap presented?

The new form was presented at the 2025 Alzheimer’s Association International Conference.

Who is involved in the development of buntanetap?

Annovis Bio Inc., a late-stage clinical company based in Malvern, Pennsylvania, is advancing buntanetap as a treatment for neurodegenerative diseases like Alzheimer’s and Parkinson’s.

What are the implications of this patent coverage for patients?

The patent coverage ensures the continued development and availability of buntanetap, potentially improving patient outcomes and quality of life in neurodegenerative diseases.

How can I learn more about Annovis Bio Inc. and its developments?

For more information, visit Annovis Bio Inc.’s website at www.annovisbio.com or follow them on LinkedIn, YouTube, and X.

Where can investors find the latest news and updates about ANVS?

Investors can find the latest news and updates relating to ANVS in the company’s newsroom at https://ibn.fm/ANVS.